The report, presented by the Alliance for Patient Access (AfPA) and titled “Biosimilars: Can They Break Through?” will include discussion on the policy issues surrounding biosimilars in the United States. Topics will include:
Given pending FDA regulations, what are the obstacles in getting biosimilars to market?
What are the concerns surrounding the labeling or prescriber information, and why is the issue of naming so hotly contested?
